A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants

NCT07662057 ↗

Phase 1 Not yet recruiting 130 enrolled Arcus Biosciences, Inc.

RandomizedSequentialDouble-blindBasic science

Summary

The purpose of this study is assess the safety and tolerability of AB102 and characterize the pharmacokinetics (PK) profile of AB102 after single and multiple ascending oral dose(s).

Timeline

Start: 2026-07
Primary completion: 2026-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AB102	Unknown	—	Oral

Indications

No indication recorded.